ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,136 | -83.0% | 4,357 | -69.5% | 0.01% | -78.3% |
| Q2 2023 | $136,155 | -96.1% | 14,287 | -95.5% | 0.02% | -96.6% |
| Q1 2023 | $3,488,672 | +15.6% | 317,152 | +55.6% | 0.67% | +14.9% |
| Q4 2022 | $3,017,010 | -28.6% | 203,852 | -7.8% | 0.58% | -29.8% |
| Q3 2022 | $4,223,000 | +10.1% | 220,985 | +22.8% | 0.83% | +7.6% |
| Q2 2022 | $3,836,000 | -9.1% | 180,016 | -17.9% | 0.77% | +3.2% |
| Q1 2022 | $4,221,000 | -16.5% | 219,136 | -10.1% | 0.75% | -1.6% |
| Q4 2021 | $5,055,000 | -72.1% | 243,736 | -67.9% | 0.76% | -49.5% |
| Q3 2021 | $18,127,000 | -12.5% | 758,763 | 0.0% | 1.51% | -10.0% |
| Q2 2021 | $20,707,000 | -18.6% | 758,763 | -13.7% | 1.68% | -13.1% |
| Q1 2021 | $25,428,000 | – | 878,948 | – | 1.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |